Fig. 3From: The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus(Reprinted with permission from Neal et al. [16])The CANVAS Program: effects of canagliflozin on HbA1c, body weight, systolic and diastolic blood pressure. HbA1c, glycated hemoglobin; CI, confidence intervalBack to article page